Anna Polli

9.3k citations
81 papers · 4.2k · 4 hit papers · h-index 25

Impact in

Papers in

    • Lung Cancer Treatments and Mutations 50
    • Lung Cancer Diagnosis and Treatment 15
    • Colorectal Cancer Treatments and Studies 19
    • Lung Cancer Research Studies 17
    • Bone health and treatments 5

Anna Polli

74 papers receiving 4.0k citations

Anna Polli's Hit Papers

Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study 2024 · 132 citations
1320+3+7Years since publication200400600

Peers

Anna Polli
Comparison fields: 5 of 92
  • Oncology 1.8k
  • Pulmonary and Respiratory Medicine 2.1k
  • Cancer Research 711
  • Endocrinology, Diabetes and Metabolism 546
  • Genetics 890
Replace Giorgio Massimini with:
Giorgio Massimini United States
Naoyoshi Onoda Japan
Gilles Romieu France
Ronald A. Morton United States
Shuji Mikami Japan
J Cuzick United Kingdom
Simon Chowdhury United Kingdom
Michael J. Demeure United States
M. Tubiana-Hulin France
Eduardo R. Pajon United States
Anna Polli relative to Giorgio Massimini United States Giorgio Massimini's profile →
Citations per field
00.5×10×20×28×
Giorgio Massimini · 1×
Citations per year

Countries citing papers authored by Anna Polli

Since Specialization
Citations

This map shows the geographic impact of Anna Polli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Polli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Polli more than expected).

Fields of papers citing papers by Anna Polli

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Polli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Polli. The network helps show where Anna Polli may publish in the future.

Co-authors

The 25 scholars most cited alongside Anna Polli, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Anna Polli Line = papers co-authored together Anna Polli links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 81 papers — load more, or switch the sort, to bring in the rest.

#Work
1
First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer
Hit paper breakdown →
2020676
2 1994471
3
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases
Hit paper breakdown →
2015468
4 2000407
5 2000243
6 2005237
7 2012136
8
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study
Hit paper breakdown →
2022136
9
Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
Hit paper breakdown →
2024132
10 2011132
11 199993
12 202286
13 200684
14 201783
15 201257
16 200050
17 199249
18 201248
19 201746
20 201641

About Anna Polli

Anna Polli is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Genetics, Cancer Research and Molecular Biology, having authored 81 papers that have together received 4.2k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (50 papers), Colorectal Cancer Treatments and Studies (19 papers), Lung Cancer Research Studies (17 papers), Lung Cancer Diagnosis and Treatment (15 papers), Estrogen and related hormone effects (15 papers), Cancer Genomics and Diagnostics (9 papers), Melanoma and MAPK Pathways (6 papers) and Bone health and treatments (5 papers). The work is most often cited by research in Oncology (1.8k citations), Pulmonary and Respiratory Medicine (2.1k citations), Cancer Research (711 citations), Endocrinology, Diabetes and Metabolism (546 citations) and Genetics (890 citations). Anna Polli has collaborated with scholars based in United States, Italy and Australia. Frequent co-authors include Alice T. Shaw, Benjamin Solomon, G. Piscitelli, Tony Mok, Carlo Ferrari, Jonathan Webster, Ikram Shah Ismail, M. F. Scanlon, Dong‐Wan Kim and Giorgio Massimini. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Thoracic Oncology, European Journal of Cancer and Future Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact